Legal Probes Launched into ADTN and CAPR Following Sharp Stock Declines

Key Facts

1Levi & Korsinsky initiated legal investigations for ADTRAN Holdings investors after a 15% stock selloff.

2Capricor shares collapsed 60% to 70% after FDA briefing documents raised concerns over Deramiocel's efficacy.

Amid mounting regulatory scrutiny and concerns over the accuracy of financial guidance, biotechnology and telecommunications firms are facing escalating legal challenges that impact shareholder confidence. Law firm Levi & Korsinsky has initiated investigations for ADTRAN Holdings investors following a 15% stock selloff triggered by preliminary Q2 2026 results missing guidance due to a delayed customer project. Separately, Capricor shares collapsed by 60% to 70% after FDA briefing documents raised efficacy concerns regarding its drug, Deramiocel.

These legal actions reflect the market's sharp reaction to operational and regulatory setbacks, where ADTN's revenue miss and CAPR's medical uncertainties led to significant capital losses. Per market data, ADTN closed at $8.42 on July 30, 2026, while CAPR stood at $6.57 at the close of July 28, 2026. The investigations focus on whether the companies potentially misled investors regarding revenue expectations and product efficacy prior to these significant price corrections.

Traders should monitor the progress of these legal probes as they may evolve into class-action lawsuits, potentially straining corporate liquidity. Based on recent data, ADTN hit a daily low of $8.20 (as of July 30, 2026), while CAPR traded between $5.67 and $7.22 (as of July 28, 2026). With no immediate catalysts in the upcoming economic calendar for these specific instruments, focus remains on official management responses or further FDA updates.